Loading...
Market
Which country will first approve GametoGen's iPSC technology outside the US by end of 2025?
2
Resolution / Starting Odds
United Kingdom • 25%
Canada • 25%
Australia • 25%
Other • 25%
Regulatory announcements or GametoGen press releases
Story
GametoGen Achieves First Live Birth Using iPSC Technology in IVF, Reducing Hormone Injections by 80% and Treatment to Three Days
Dec 16, 2024, 04:09 PM
GametoGen, a next-generation IVF startup, has announced the first successful live birth using its innovative technology, which utilizes induced pluripotent stem cell (iPSC)-derived ovarian cells. This groundbreaking achievement marks a significant milestone in reproductive technology, as the company claims it is the first human birth resulting from iPSC technology. The new method reportedly replaces 80% of the hormone injections typically required in traditional IVF and shortens treatment cycles to just three days. The announcement has garnered attention for its potential to revolutionize access to IVF and improve outcomes for families seeking fertility assistance.
View original story
Similar markets
Japan • 25%
USA • 25%
EU • 25%
Other • 25%
United Kingdom • 25%
Canada • 25%
Australia • 25%
Other • 25%
United States • 25%
European Union • 25%
China • 25%
Other • 25%
Japan • 25%
USA • 25%
China • 25%
Other • 25%
United States • 25%
European Union • 25%
China • 25%
Other • 25%
United States • 25%
China • 25%
European Union • 25%
Other • 25%
USA • 25%
EU • 25%
China • 25%
Other • 25%
UK • 25%
Germany • 25%
Canada • 25%
Other • 25%
United Kingdom • 25%
Canada • 25%
Australia • 25%
Other • 25%
United States • 25%
China • 25%
European Union • 25%
Other • 25%
United States • 25%
Canada • 25%
Germany • 25%
Other • 25%
United States • 25%
European Union • 25%
United Kingdom • 25%
Other • 25%